CAD and plasma cell myeloma: Bortezomib (Velcade®), carfilzomib (Kyprolis®) and ixazomib (Ninlaro®) significantly improved the clinical outcome of multiple myeloma patients by non-selectively targeting CPs and killing cancer cells that strictly rely on high-capacity protein degradation [44,45].